WO2001078711A2 - Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson - Google Patents

Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson Download PDF

Info

Publication number
WO2001078711A2
WO2001078711A2 PCT/US2001/040538 US0140538W WO0178711A2 WO 2001078711 A2 WO2001078711 A2 WO 2001078711A2 US 0140538 W US0140538 W US 0140538W WO 0178711 A2 WO0178711 A2 WO 0178711A2
Authority
WO
WIPO (PCT)
Prior art keywords
pde5
inhibitors
pde
dopa
methyl
Prior art date
Application number
PCT/US2001/040538
Other languages
English (en)
Other versions
WO2001078711A3 (fr
Inventor
H. H. Roylance
Original Assignee
Lilly Icos, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos, Llc. filed Critical Lilly Icos, Llc.
Priority to JP2001576012A priority Critical patent/JP2004500425A/ja
Priority to DE60124085T priority patent/DE60124085D1/de
Priority to AU2001255849A priority patent/AU2001255849B8/en
Priority to AU5584901A priority patent/AU5584901A/xx
Priority to CA002407031A priority patent/CA2407031A1/fr
Priority to EP01929063A priority patent/EP1278522B1/fr
Publication of WO2001078711A2 publication Critical patent/WO2001078711A2/fr
Publication of WO2001078711A3 publication Critical patent/WO2001078711A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to novel therapeutic methods for treating Parkinson's Disease by administering cyclic GMP- specific phosphodiesterase inhibitor compounds.
  • Parkinson's Disease is a progressive degenerative disorder of the central nervous system (CNS) characterized by tremor and impaired muscular coordination. It is fatal if untreated. PD has been reported to affect approximately one percent of Americans over fifty years of age, but unrecognized early symptoms of the disease may be present in as many as ten percent of those over 60 years of age. The current prediction is that one to one and one-half million persons in the United States may be suffering from PD. The disease may appear at any age, but the risk of developing it increases with age. The occurrence of PD is therefore expected to increase in the next one-half century as the average age of individuals in developed countries progressively increases.
  • Cogwheel rigidity refers to increased tone that is felt by the examiner as a ratchet-like resistance during passive range of motion Bradykinesia means slowed nonvo tional and/or volitional movements
  • the masked faces of PD are an example of slowed nonvohtional movement
  • the mean duration of PD is about fourteen years However, without treatment, the period between presentation of clinical features and death is reduced to about nine years The rate of disease progression is believed to be directly correlated to the rate of neuron loss
  • Symptomatic therapies are the most common form of treatment for PD These remedies attempt to fulfill the basic dictate of traditional medicine, to relieve suffering These drugs are designed to be used as either monotherapy or adjunctive symptomatic therapy but have little, if any, beneficial effects on underlying disease cause or pathogenesis
  • the symptomatic compounds can be divided into two groups on the basis of their pharmacologic action - dopammergic drugs and nondopaminergic drugs Most symptomatic PD drugs attempt to replenish, mimic, or enhance the effects of brain dopamine, a neurotransmitter, because PD is thought to be due to defective dopammergic transmission in the substantia nigra of the basal ganglia Dopamine itself is neither well absorbed in the gastrointestinal tract nor effectively transported across the blood-brain barrier L-dopa is dopamine precursor therapy L-dopa crosses the blood-brain barrier penetrating into the brain, where it is converted to dopamine via the enzyme dopa decarboxylase L-dopa has poor bio
  • L-dopa is formulated with a decarboxylase inhibitor.
  • the decarboxylase inhibitor carbidopa is contained in virtually all L-dopa products prescribed during the last 20 years.
  • L-dopa has served as the mainstay of PD therapy.
  • long term treatment with L-dopa often results in disabling complications.
  • Many patients develop unsustained or unpredictable responses to L-dopa along with drug-induced involuntary movements. It has even been postulated by Mena, et al., Mov Disord 7:23 (1992), that L-dopa may be neurotoxic and thereby accelerates nigral neuronal degeneration.
  • dopamine agonists have been developed for use as monotherapy in early PD to postpone the need to initiate L-dopa therapy and for use as adjunctive therapy later in the disease to permit reduction of L-dopa dosing or enhancement of beneficial dopaminergic effects.
  • Agonists directly stimulate dopamine receptors within the brain, and thus their action is independent of L-dopa.
  • Blockade of other metabolic enzymatic pathways can also be used to enhance the effects of L-dopa or to maintain brain dopamine levels.
  • One of the central metabolic pathways for dopamine is mediated via the enzyme monoamine oxidase type B (MAOB).
  • MAOB monoamine oxidase type B
  • Another MAOB inhibitor, lazabemide was initially tested as adjunctive therapy in PD, but it is not being actively developed at this time. Hubble, JP, Med Clinics of North America 83(2):525-536 (1999).
  • the compound rasagiline also inhibits the oxidative monoamine metabolic enzymes. Rasagiline's effects in early untreated PD are being investigated. Hubble, supra.
  • Cyclic nucleotide phosphodiesterases are essential regulators of cyclic nucleotide-dependent signal transduction processes. They terminate the action of the second messengers adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) by hydrolyzing them to their respective 5'- nucleoside monophosphates. Based on their biological properties, the PDEs may be classified into several general families.
  • Ca 2 7calmodulin-stimulated PDE (Type I), cGMP-stimulated PDE (Type II), cGMP-inhibited PDE (Type III), cAMP-specific PDE (Type IV), cGMP-specific
  • dopamine agonists with phosphodiesterase inhibitors was examined after it was discovered that the striatal dopaminergic receptor was closely associated with an adenylate cyclase.
  • the actions of dopamine are mediated by an adenylate cyclase which produces cyclic AMP.
  • U.S. Patent 4,147,789 discloses the combination of 6-methyl-8- thiomethyl-ergolene derivatives with nonselective phosphodiesterase inhibitors for treatment of PD.
  • U.S. Patent 4,147,789 does not disclose using specific phosphodiesterase inhibitors nor does it disclose combining L-dopa with phosphodiesterase inhibitors.
  • the present invention provides novel therapeutic uses for Type V PDE inhibitors in patients suffering from PD.
  • the invention provides methods of preventing and/or slowing the progression of PD or reducing or eliminating clinical symptoms of PD by administering a therapeutically effective amount of one or more Type V PDE (PDE5) inhibitor(s) of the invention.
  • PDE5 Type V PDE
  • a "clinical symptom" of PD includes tremor, cogwheel rigidity, bradykinesia, poor postural reflexes, and any other clinically defined physical or mental manifestation of PD.
  • IC 50 is defined as the concentration of a compound that results in 50% enzyme inhibition, in a single dose response experiment.
  • the IC 50 value therefore is a measure of the potency of a compound to inhibit PDEs, including PDE5. Determining the IC 50 value of a compound is readily carried out by a known in vitro methodology generally described in Cheng et al., Biochem Pharmacology 22:3099-3108 (1973).
  • the term “inhibiting” or “inhibits” refers to blocking the enzymatic activity of PDE5 to a sufficient degree to reduce a clinical symptom of PD or to prevent the recurrence of a clinical symptom of PD
  • a pharmaceutically effective amount represents an amount of a compound that is capable of inhibiting PDE5, and causes an improvement in a clinical symptom of PD and/or prevents or reduces recurrence of the symptom
  • PDE5 inhibitor refers to a compound that inhibits PDE5
  • a PDE5 inhibitor useful in the present invention is a compound that inhibits PDE5 and has an IC 50 value against human recombinant PDE5 of about 10 nM or less
  • the IC 50 value of the PDE5 inhibitor is about 5 nM or less, more preferably about 3 nM or less, and most preferably about 1 nM or less
  • Most preferred PDE5 inhibitors are selective PDE5 inhibitors, i e , those that inhibit PDE5, but do not significantly inhibit other PDE enzymes, particularly PDE6 and PDE 1c
  • a preferred PDE5 inhibitor exhibits a PDE6/PDE5 and a PDE1 c/PDE5 IC ⁇ inhibition quotient of at least 200, and can range to 1 ,000 or greater
  • the PDE6/PDE5 IC 50 inhibition quotient is the ratio of the IC 50 value of a compound vs PDE6 to the IC 50
  • the compound has a PDE6/PDE5 and a PDE1 c/PDE5 IC 50 inhibition quotient of at least 100 and an IC 50 for PDE5 of about 5 nM or less, e g , about 0 1 to about 5 nM Therefore, for preferred inhibitors, the IC 50 value of the PDE5 inhibitor is about 100 times less than the IC 50 value against PDE6 or PDEIc, more preferably about 500 times less than the IC 50 value against PDE6 or PDEIc, and most preferably about 1000 times less than the IC 50 value against PDE6 or PDEIc
  • PDE5 inhibitors useful in the present invention vary significantly in chemical structure and the use of a PDE5 inhibitor in the present method is not dependent on a particular chemical structure
  • preferred compounds having the ability to inhibit PDE5 include compounds having the structural formula (I)
  • R 1 is methyl or ethyl
  • R 2 is n-propyl
  • R 3 is ethyl, n-propyl, or ailyl
  • R 4 is
  • R 13 is selected from the group consisting of hydrogen, halogen, and C h alky!;
  • R 14 is selected from the group consisting of hydrogen, C ⁇ alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, halo, C 3 . 8 cycloalkyl, C 3 . 8 cycloalkylC 1 .
  • aryl is phenyl or phenyl substituted with one to three substituents independently selected from the group consisting of halogen, C ⁇ alkyl, C ⁇ alkoxy, and methylenedioxy, and heteroarylC Lj alkyl, wherein heteroaryl is thienyl, furyl, or pyridyl, each optionally substituted with one to three substituents independently selected from the group consisting of halogen, C ⁇ alkyl, and C ⁇ alkoxy.
  • R 15 represents an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring
  • the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen;
  • R 16 represents hydrogen or C ⁇ alkyl, or R 14 and R 16 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.
  • Preferred compounds of structural formula (II) are those wherein R 13 is hydrogen, halogen, or C, 6 alkyl; R 14 is hydrogen or C h alky!; R 15 is the bicyclic ring
  • Preferred compounds of structural formula (II) include:
  • the compounds of structural formula (II) are particularly advantageous due to their selectivity in inhibiting PDE5 over other PDE enzymes.
  • Still other exemplary PDE5 inhibitors useful in the present method are those disclosed in Daugan et al. U.S. Patent No. 6,001 ,847;
  • ring C represents a 5- or 6-membered heteroaryl group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;
  • R 17 represents hydrogen or halogen
  • R 19 is selected from the group consisting of hydrogen, halogen, OR h , C ⁇ alkyl, NO 2 , and NR h R'; or R 18 and R 19 are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;
  • R 21 is hydrogen, or R 20 and R 21 are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom; Het represents a 5- or 6-membered heterocyc c group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and is optionally substituted with C, 4 alkyl,
  • R h and R' can be the same or different, and are independently selected from hydrogen and C, 6 alkyl,
  • C is a heteroaryl group containing at least one nitrogen or sulfur
  • R 19 is hydrogen
  • R 18 is selected from the group consisting of NR h R' and a 5- or 6-membered heterocychc group containing at least one nitrogen optionally substituted with C ⁇ alkyl
  • the PDE5 inhibitors may be concurrently administered with other drugs, including other known anti-PD drugs, in which case the dosage of each agent required to exert a therapeutic effect during combinative therapy may be less than the dosage necessary for monotherapeutic effectiveness
  • drugs for concurrent administration include, but are not limited to, L-dopa, carbo-levo, apomorphine, pirebedil, bromocriptine, carbergohne, pramipexole, ropinirole, selegiline, lazabemide, rasagiline, sildenafil citrate (Viagra), caffeine, Mirapex, Naprelan, Oxybutin and aspirin
  • the invention further provides uses of PDE5 inhibitors in the manufacture of a medicament for treating PD
  • PDE5 inhibitors possess desirable physical and biological properties, e g , a sufficient water solubility, bioavailability, and metabolic stability, for therapeutic use in the treatment of PD
  • Anti-PD therapeutically effective amounts of PDE5 inhibitors include amounts effective for slowing or preventing the progression of PD and amounts effective to alleviate or reduce the clinical symptoms of PD PDE5 inhibitors can be administered to humans at doses ranging from about 0 1 mg to about 1000 mg daily or more preferably at doses ranging from about 1 mg to about 100 mg daily for adults Even more preferably, doses range from about 2mg to about 20 mg over a 24 hour period Most preferable are doses calculated to provide an effective circulating blood level Equivalent dosing of PDE5 inhibitors can be administered at longer intervals, e g , larger doses once or twice weekly The dosage of the drug may be increased or decreased, and the duration of treatment
  • the specific dose may be calculated according to body weight, body surface area or organ size Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art without undue experimentation Appropriate dosages may be ascertained through use of established assays for determining blood level dosages in conjunction with appropriate dose- response data The final dosage regimen will be determined by the attending physician, considering various factors which modify the action of drugs, e g , the drug ' s specific activity, the severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of the clinical symptoms, time of administration and other clinical factors.
  • PDE5 inhibitors may be administered systemically via, e.g., oral, intravenous, intramuscular or subcutaneous routes.
  • the drug may be aerosolized for pulmonary administration, formulated in a spray for nasal administration, administered intraventricularly or intrathecally into the cerebrospinal fluid, or administered intravenously via continuous infusion pump.
  • the drugs may also be administered topically via, e.g., drops
  • PDE5 inhibitors and another anti-PD agent can be administered simultaneously or sequentially.
  • the compounds are usually administered in the form of pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one active ingredient.
  • These compositions can be administered by a variety of routes including oral, buccal, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions.
  • compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • the active ingredient usually is mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), oint- ments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • compositions used in the invention can be formulated to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions preferably are formulated in a unit dosage form.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the active compounds generally are effective over a wide dosage range. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances.
  • Example 1 describes the preparation of
  • Example 2 describes an assay for PDE5 activity.
  • Example 3 describes assays to measure the effects of PDE5 inhibitors.
  • Example 4 describes administration of a PDE5 inhibitor compound to a patient suffering from PD.
  • yeast transformation vector employed which is derived from the basic ADH2 plasmid described in V. Price et al., Methods in Enzymology, 185, pages 308-318 (1990) incorporated yeast ADH2 promoter and terminator sequences rather than ADH1 promoter and terminator sequences and the Saccharomyces cerevisiae host was the protease-deficient strain BJ2-54 deposited on August 31 , 1998 with the American Type Culture Collection, Manassas, Virginia, under accession number ATCC 74465.
  • Transformed host cells were grown in 2X SC-leu medium, pH 6.2, with trace metals, and vitamins. After 24 hours, YEP medium containing glycerol was added to a final concentration of 2X YEP/3% glycerol. Approximately 24 hours later, cells were harvested, washed, and stored at -70 °C.
  • Cell pellets (29 g) were thawed on ice with an equal volume of lysis buffer (25 mM Tris-CI, pH 8, 5 mM MgCI 2 , 0.25 mM dithiothreitol, 1 mM benzamidine, and 10 ⁇ M ZnSO 4 ).
  • lysis buffer 25 mM Tris-CI, pH 8, 5 mM MgCI 2 , 0.25 mM dithiothreitol, 1 mM benzamidine, and 10 ⁇ M ZnSO 4 .
  • Cells were lysed in a microfluidizer with N 2 at 20,000 psi. The lysate was centrifuged and filtered through 0.45 ⁇ M disposable filters. The filtrate was applied to a 150 ml column of Q Sepharose Fast Flow (Pharmacia).
  • the column was washed with 1 .5 volumes of Buffer A (20 mM Bis-Tris Propane, pH 6.8, 1 mM MgCI 2 , 0.25 mM dithiothreitol, 10 ⁇ M ZnSO 4 ) and eluted with a step gradient of 125 mM NaCI in Buffer A followed by a linear gradient of 125-1000 mM NaCI in Buffer A.
  • Buffer A (20 mM Bis-Tris Propane, pH 6.8, 1 mM MgCI 2 , 0.25 mM dithiothreitol, 10 ⁇ M ZnSO 4 .
  • Active fractions from the linear gradient were applied to a 180 ml hydroxylapatite column in Buffer B (20 mM Bis-Tris Propane (pH 6.8), 1 mM MgCI 2 , 0.25 mM dithiothreitol, 10 ⁇ M ZnSO 4 , and 250 mM KCI). After loading, the column was washed with 2 volumes of Buffer B and eluted with a linear gradient of 0-125 mM potassium phosphate in Buffer B.
  • Buffer B 20 mM Bis-Tris Propane (pH 6.8), 1 mM MgCI 2 , 0.25 mM dithiothreitol, 10 ⁇ M ZnSO 4 , and 250 mM KCI.
  • Active fractions were pooled, precipitated with 60% ammonium sulfate, and resuspended in Buffer C (20 mM Bis-Tris Propane, pH 6.8, 125 mM NaCI, 0.5 mM dithiothreitol, and 10 ⁇ M ZnSO 4 ).
  • Buffer C 20 mM Bis-Tris Propane, pH 6.8, 125 mM NaCI, 0.5 mM dithiothreitol, and 10 ⁇ M ZnSO 4 ).
  • the pool was applied to a 140 ml column of Sephacryl S-300 HR and eluted with Buffer C. Active fractions were diluted to 50% glycerol and stored at -20 °C. The resultant preparations were about 85% pure by SDS-PAGE.
  • PDE5 activity can be measured by standard assays in the art. For example, specific activity of any PDE can be determined as follows. PDE assays utilizing a charcoal separation technique are performed essentially as described in Loughney, et al., J. Biol. Chem. 277:796-806 (1996). In this assay, PDE5 activity converts [ 32 P]cGMP to
  • [ 32 P]5'GMP in proportion to the amount of PDE5 activity present.
  • the [ 32 P]5'GMP is then quantitatively converted to free [ 32 P] phosphate and unlabeled adenosine by the action of snake venom 5'-nucleotidase.
  • the amount of [ 32 P] phosphate liberated is proportional to enzyme activity.
  • the assay is performed at 30°C in a 100 ⁇ L reaction mixture containing (final concentrations) 40 mM Tris-CI (pH 8.0), 1 ⁇ M ZnSO 4 , 5 mM MgCI 2 , and 0.1 mg/ml bovine serum albumin.
  • PDE5 is present in quantities that yield ⁇ 30% total hydrolysis of substrate (linear assay conditions).
  • the assay is initiated by addition of substrate (1 mM [ 32 P]cGMP), and the mixture is incubated for twelve minutes. Seventy-five (75) ⁇ g of Crotalus atrox venom is then added, and the incubation is continued for three more minutes (fifteen minutes total).
  • the reaction is stopped by addition of 200 ⁇ L of activated charcoal (25 mg/ml suspension in 0.1 M NaH 2 PO 4 , pH 4). After centrifugation (750 X g for three minutes) to sediment the charcoal, a sample of the supernatant is taken for radioactivity determination in a scintillation counter and the PDE5 activity is calculated.
  • inhibitors of the present invention on enzymatic activity of PDE5 preparations can be assessed in either of two assays which differ from each other principally on the basis of scale and provide essentially the same results in terms of IC 50 values. Both assays involve modification of the procedure of Wells et al., Biochim. Biophys. Ada, 384, 430 (1975). The first of the assays is performed in a total volume of 200 ⁇ l containing 50 mM Tris pH 7.5, 3 mM Mg acetate, 1 mM EGTA, 50 ⁇ g/ml snake venom nucleotidase and 50 nM [ 3 H]-cGMP (Amersham).
  • a second, microplate PDE assay uses Multiscreen plates and a vacuum manifold.
  • the assay (100 ⁇ l) contains 50 mM Tris pH 7.5, 5 mM Mg acetate, 1 mM EGTA and 250 ⁇ g/ml snake venom nucleotidase.
  • the other components of the reaction mixture are as described above.
  • the total volume of the assay is loaded on a QAE Sephadex microcolumn plate by filtration. Free radioactivity is eluted with 200 ⁇ l of water from which 50 ⁇ l aliquots are analyzed by scintillation counting as described above.
  • a patient who was administered a PDE5 inhibitor of the invention noted an improvement in his Parkinson's symptoms, i.e., a reduction in his symptoms.
  • the PDE5 inhibitor was 5-(2-ethoxy-5-(4-methyl- 1 -p ⁇ peraz ⁇ nylsulphonyl)phenyl)-1 -methyl-3-n-propyl-1 ,6-d ⁇ hydro-7H- pyrazolo[4,3-d]pyr ⁇ m ⁇ d ⁇ n-7-one, otherwise known as sildenafil citrate (Viagra®)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne généralement des méthodes de soins destinées au traitement de la maladie de Parkinson consistant à administrer des composés inhibiteurs de phosphodiestérase spécifique de GMP cyclique.
PCT/US2001/040538 2000-04-19 2001-04-17 Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson WO2001078711A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001576012A JP2004500425A (ja) 2000-04-19 2001-04-17 パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
DE60124085T DE60124085D1 (de) 2000-04-19 2001-04-17 Pde-v hemmer zur behandlung von morbus parkinson
AU2001255849A AU2001255849B8 (en) 2000-04-19 2001-04-17 PDE-V inhibitors for treatment of Parkinson's Disease
AU5584901A AU5584901A (en) 2000-04-19 2001-04-17 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CA002407031A CA2407031A1 (fr) 2000-04-19 2001-04-17 Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
EP01929063A EP1278522B1 (fr) 2000-04-19 2001-04-17 Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19818000P 2000-04-19 2000-04-19
US60/198,180 2000-04-19

Publications (2)

Publication Number Publication Date
WO2001078711A2 true WO2001078711A2 (fr) 2001-10-25
WO2001078711A3 WO2001078711A3 (fr) 2002-07-04

Family

ID=22732318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040538 WO2001078711A2 (fr) 2000-04-19 2001-04-17 Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson

Country Status (9)

Country Link
US (2) US20020006926A1 (fr)
EP (1) EP1278522B1 (fr)
JP (1) JP2004500425A (fr)
CN (1) CN1436080A (fr)
AT (1) ATE343388T1 (fr)
AU (2) AU2001255849B8 (fr)
CA (1) CA2407031A1 (fr)
DE (1) DE60124085D1 (fr)
WO (1) WO2001078711A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733728A2 (fr) * 2001-07-23 2006-12-20 Bayer HealthCare AG Utilisation d'imidazotriazinones 2-alcoxyphenyl substituées en tant qu'inhibiteurs de la phosphodiestérase
WO2008144061A2 (fr) * 2007-05-18 2008-11-27 Vivus, Inc. Nouvelles compositions comprenant un inhibiteur de phosphodiestérase-5 et leur utilisation dans des procédés de traitement
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
AU2007217349B2 (en) * 2006-02-21 2013-05-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
WO2018160067A1 (fr) * 2017-03-02 2018-09-07 Universiteit Van Amsterdam Augmentation spécifique de la synthèse de la dopamine par ciblage du récepteur de la guanylate cyclase 2c dans le traitement de la maladie de parkinson

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020702A2 (fr) 2001-08-31 2003-03-13 The Rockefeller University Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
WO2007025103A2 (fr) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Composes organiques
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
JP2010509399A (ja) * 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
HRP20131073T1 (hr) 2007-12-06 2014-01-31 Takeda Pharmaceutical Company Limited Organski spojevi
WO2009073210A1 (fr) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Composés organiques
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
CA2740396A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composes organiques
MA32937B1 (fr) * 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
EP2400970A4 (fr) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc Inhibiteur de pde 1 pour troubles ophtalmiques
WO2010132127A1 (fr) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Composés organiques
WO2011016861A2 (fr) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Nouvelles protéines régulatrices et nouveaux inhibiteurs
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2011153135A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2011153136A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
US20150086481A1 (en) * 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
WO2014127331A1 (fr) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Nouvelles utilisations
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6437519B2 (ja) 2013-03-15 2018-12-12 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
JP6810613B2 (ja) 2014-06-20 2021-01-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN107106563B (zh) 2014-09-17 2021-05-25 细胞内治疗公司 化合物和方法
MX2017007377A (es) 2014-12-06 2017-11-06 Intra-Cellular Therapies Inc Compuestos organicos.
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147789A (en) * 1974-03-14 1979-04-03 Sandoz Ltd. 6-Methyl-8-thiomethyl-ergolene derivatives
WO1999031065A1 (fr) * 1997-12-12 1999-06-24 Cell Pathways, Inc. Derives de n-benzyl-3-indenylacetamides pour traiter des neoplasies
WO2001032170A1 (fr) * 1999-09-13 2001-05-10 Swope David M Composition et procede pour la reduction de la symptomatologie neurologique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038963B1 (fr) 1993-05-27 2009-08-05 Board Of Regents Of The University Of Washington Phosphodiésterase de fixation du monophosphate de guanosine cyclique et avec specificité pour celui-ci et procédé d'obtention
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
ATE303365T1 (de) * 1995-12-28 2005-09-15 Fujisawa Pharmaceutical Co Benzimidazolderivate
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
EP0992240A4 (fr) 1997-05-29 2003-04-16 Mochida Pharm Co Ltd Agent therapeutique destine a traiter l'anerection
JP2002509553A (ja) 1997-10-27 2002-03-26 藤沢薬品工業株式会社 ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物
DE19881732D2 (de) 1997-11-12 2000-08-24 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
WO1999026946A1 (fr) 1997-11-26 1999-06-03 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE A ACTIVITE INHIBITRICE SUR LA cGMP-PDE
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
ZA9810766B (en) 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
PL339836A1 (en) 1998-02-19 2001-01-02 Eisai Co Ltd Phtalazine compounds and therapeutic agents suitable to treat erection disorders
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
EP1080069B1 (fr) 1998-04-20 2003-03-19 Fujisawa Pharmaceutical Co., Ltd. Derives d'acide anthrenilique utilises comme inhibiteurs de cgmp-phosphodiesterase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147789A (en) * 1974-03-14 1979-04-03 Sandoz Ltd. 6-Methyl-8-thiomethyl-ergolene derivatives
WO1999031065A1 (fr) * 1997-12-12 1999-06-24 Cell Pathways, Inc. Derives de n-benzyl-3-indenylacetamides pour traiter des neoplasies
WO2001032170A1 (fr) * 1999-09-13 2001-05-10 Swope David M Composition et procede pour la reduction de la symptomatologie neurologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SWOPE, D.M.: "Preliminary report: Use of sildenafil to treat dyskinesias in patients with Parkinson's disease" NEUROLOGY, vol. 54, no. 7(3), 11 April 2000 (2000-04-11), pages A90-A91, XP001018724 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733728A3 (fr) * 2001-07-23 2007-03-21 Bayer HealthCare AG Utilisation d'imidazotriazinones 2-alcoxyphenyl substituées en tant qu'inhibiteurs de la phosphodiestérase
EP1733728A2 (fr) * 2001-07-23 2006-12-20 Bayer HealthCare AG Utilisation d'imidazotriazinones 2-alcoxyphenyl substituées en tant qu'inhibiteurs de la phosphodiestérase
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
AU2007217349B9 (en) * 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
EP1991214B1 (fr) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Utilisation de rasagiline pour traiter une atrophie multisystématisée
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007217349B2 (en) * 2006-02-21 2013-05-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
WO2008144061A3 (fr) * 2007-05-18 2009-02-12 Vivus Inc Nouvelles compositions comprenant un inhibiteur de phosphodiestérase-5 et leur utilisation dans des procédés de traitement
US8440671B2 (en) 2007-05-18 2013-05-14 Vivus, Inc. Compositions comprising a phoshodiesterase-5 inhibitor and their use in methods of treatment
AU2008254424B2 (en) * 2007-05-18 2012-12-20 Vivus, Inc. Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
WO2008144061A2 (fr) * 2007-05-18 2008-11-27 Vivus, Inc. Nouvelles compositions comprenant un inhibiteur de phosphodiestérase-5 et leur utilisation dans des procédés de traitement
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
US9259418B2 (en) 2008-06-06 2016-02-16 Pharmatwo B Ltd Pharmaceutical compositions for treatment of Parkinson's disease
WO2018160067A1 (fr) * 2017-03-02 2018-09-07 Universiteit Van Amsterdam Augmentation spécifique de la synthèse de la dopamine par ciblage du récepteur de la guanylate cyclase 2c dans le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
US6492371B2 (en) 2002-12-10
CA2407031A1 (fr) 2001-10-25
WO2001078711A3 (fr) 2002-07-04
US20020006926A1 (en) 2002-01-17
JP2004500425A (ja) 2004-01-08
AU2001255849B2 (en) 2005-12-22
AU5584901A (en) 2001-10-30
AU2001255849B8 (en) 2006-04-27
CN1436080A (zh) 2003-08-13
EP1278522B1 (fr) 2006-10-25
US20020077274A1 (en) 2002-06-20
EP1278522A2 (fr) 2003-01-29
DE60124085D1 (de) 2006-12-07
ATE343388T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
US6492371B2 (en) Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of Parkinson's Disease
AU2001255849A1 (en) PDE-V inhibitors for treatment of Parkinson's Disease
US20080153813A1 (en) 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS
Chen et al. Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro
EP0729758A2 (fr) Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US7115621B2 (en) Chemical compounds
BG107077A (bg) Използуване на пиридо /3,2-е/ - пиразинони като инхибитори на фосфодиестераза 5 за лечение на еректилна дисфункция
US20050209243A1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
EP1313478A2 (fr) Traitement de la migraine par des inhibiteurs de pde5
KR20060037252A (ko) 불안 장애의 치료 방법
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
Kim Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey
JP4339679B2 (ja) Ｐｄｅ５阻害剤としてのカルボリン誘導体
JP3276762B2 (ja) イソキノリン誘導体を含有する医薬組成物
EP0869785A1 (fr) 4-hydroxycoumarine-3-carboxamides pour le traitement du diabete sucre
Polosa et al. Adenosine as a pro-inflammatory mediator in asthma
JP3782001B2 (ja) イソキノリン誘導体を含有する抗鬱、抗不安剤
Magnussen et al. Theophyllamine and the antiparkinsonian response to levodopa treatment
JPH04342526A (ja) 四肢の末梢循環改善剤及び血管攣縮抑制剤
JP2002179570A (ja) イソキノリン誘導体を含有する抗アレルギー、抗喘息、抗炎症剤
KR20020095469A (ko) 발기부전을 치료하기 위한, 피리도[3,2-ｅ]-피라지논의포스포디에스테라제 5의 억제제로서의 용도
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2001 576012

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2407031

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001929063

Country of ref document: EP

Ref document number: 2001255849

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018112226

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001929063

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001255849

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001929063

Country of ref document: EP